Revolutionizing Depression Treatment: Combining Digital Therapy and Laser Stimulation
Austin, TX, USA / Hamburg, Germany, January 29, 2025
A groundbreaking clinical trial conducted by neuroscientists at the University of Texas at Austin has demonstrated how combining deprexis, the leading digital therapy for depression, with transcranial infrared laser stimulation (TILS) can significantly enhance treatment outcomes. The study (read here) revealed that this innovative pairing resulted in a 30% greater reduction in depression symptoms, compared to using a placebo laser treatment. The trial offers a glimpse into the future of neuropsychotherapeutic mental health care.
Advancing the Science of Depression Treatment
TILS is a non-invasive technique that targets the right prefrontal cortex, enhancing energy metabolism and oxygenation in brain areas critical for cognitive control and emotional regulation. The laser activation creates ideal conditions for deprexis to engage these neural pathways more effectively, empowering patients to get the most out of the cognitive and behavioral therapy (CBT) techniques conveyed by deprexis. The result is a powerful synergy that leverages both the biological and cognitive-behavioral dimensions of depression treatment, offering patients more effective relief.
The study sheds new light on the biological mechanisms underlying deprexis’s effectiveness in reducing depression. Mario Weiss, CEO and founder of GAIA, explained: “deprexis was designed to engage neural pathways that govern emotion regulation and cognitive control. By tapping into the brain’s remarkable capacity for neuroplasticity, deprexis drives lasting improvements through the formation and strengthening of synaptic connections over time. It makes sense that this works even better when these same brain areas are primed by biological interventions like TILS.”
GAIA’s Commitment to Innovation
“This research is an exciting validation of our vision for innovative mental health care,” said Weiss. “The synergy between deprexis and TILS showcases the potential of integrating cutting-edge digital therapy with biological interventions to transform mental health care. We remain committed to advancing these kinds of pioneering approaches to improve treatment access and quality worldwide.”
About deprexis
deprexis is a trusted and globally recognized digital therapy for individuals experiencing depression. It offers personalized, interactive interventions based on CBT principles, empowering patients to take an active role in their mental health journey.
About GAIA:
GAIA is a leader in the development of digital treatments, with over 25 years of experience creating innovative, research-backed solutions for mental and behavioral health. GAIA’s products, including deprexis, are used worldwide to deliver measurable, meaningful outcomes in routine clinical care.
For media inquiries, please contact:
Stan Sugarman
GAIA AG
Hans-Henny-Jahnn-Weg 53
22085 Hamburg
E-Mail: presse@gaia-group.com
Telefon: +49 40 3510520
